Loading clinical trials...
Loading clinical trials...
A Phase 1b, Randomized, Single-blind, Placebo-controlled, Multiple Ascending Dose (MAD) Study to Assess the Steady-State Pharmacokinetics and DQ8 Blocking Efficacy of Orally Administered IMT-002 in Patients With Type 1 Diabetes and HLA-DQ8
Conditions
Interventions
350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule
700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule
+2 more
Locations
3
United States
Prosciento, Inc.
Chula Vista, California, United States
Barbara Davis Center
Aurora, Colorado, United States
Rainier Clinical Research Center
Renton, Washington, United States
Start Date
November 9, 2020
Primary Completion Date
May 11, 2021
Completion Date
July 31, 2021
Last Updated
August 25, 2021
NCT03648918
NCT06408207
NCT05777330
NCT03811470
NCT07319286
NCT03782636
Lead Sponsor
Immunomolecular Therapeutics, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions